Floatz logo

Tisagenlecleucel

Acute Biphenotypic Leukemia

M.D. Anderson Cancer CenterCell therapyPhase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
89/ 100

Competitive context

31 Active assets in the Acute Biphenotypic Leukemia cohort.

Asset / SponsorPhaseRating
Fludarabine
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase 2/3BB
Cytosin-Arabinosid
University of Washington
Phase 2BB
FILGRASTIM
Ossium Health, Inc.
Phase 2BB
ETOPOSIDE
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase 2/3BB
Busulphan
Ossium Health, Inc.
Phase 2BB

View all 44 →

Same molecule, other indications

Tisagenlecleucel is also rated in:

non-Hodgkin lymphomaDormant
BB
Indicative ·
66 / 100
View asset →
Diffuse Large B Cell LymphomaDormant
BB
Indicative ·
64 / 100
View asset →
B-cell Acute Lymphoblastic LeukemiaDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →